Comparative Effectiveness of Intravenous Immunoglobulin vs Steroids in the Treatment of Pediatric Acute (Non-COVID) Myocarditis: A Pediatric Health Information Systems Database Study
Access to this document is restricted. Some items have been embargoed at the request of the author, but will be made publicly available after the "No Access Until" date.
During the embargo period, you may request access to the item by clicking the link to the restricted file(s) and completing the request form. If we have contact information for a Cornell author, we will contact the author and request permission to provide access. If we do not have contact information for a Cornell author, or the author denies or does not respond to our inquiry, we will not be able to provide access. For more information, review our policies for restricted content.
OBJECTIVES: To describe the epidemiology of acute, non-COVID-19 myocarditis in hospitalized children and to evaluate the association of administration of intravenous immunoglobulin (IVIg) and/or steroids with hospital mortality. STUDY DESIGN: We conducted a retrospective cohort study using the Pediatric Health Information System (PHIS) database. Children (ages 0-18 years) coded for myocarditis from 2012-2022 were included. Patients missing pharmacy data or those with a diagnosis of COVID-19 were excluded. Data included demographics, complex chronic conditions, medications, and clinical course. Patients were divided into 4 treatment categories: (1) no IVIg or steroids, (2) steroids, (3) IVIg, and (4) both IVIg and steroids. RESULTS: 2294 children were included. Treatment groups were (1 - none) 8% (189/2294); (2 - steroids) 20% (450/2294); (3 - IVIg) 25% (578/2294); and (4 - IVIg and steroids) 47% (1077/2294). In-hospital mortality was 8%. The proportion of patients who received IVIg alone decreased significantly over the study period (tau= -0.527, p=0.03). After adjusting for sex, race, hospital region, age at admission, length of stay, need for intensive care, presence of a complex chronic condition, and use of anti-arrhythmic medication, the receipt of IVIg alone (OR 0.24, 95% CI 0.13-0.42) or the combination of IVIg and steroids (OR 0.60, 95% CI 0.42-0.87) was independently associated with decreased mortality compared with steroid use alone. These associations were also seen in a sub-group of children with acute fulminant myocarditis. CONCLUSIONS: In-hospital mortality from acute myocarditis in children remains important. Although IVIg use has decreased over time, IVIg with or without steroids is associated with improved survival.